Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 2Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 6ibrutinib 4venetoclax 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Sirolimus 2Mycophenolic Acid 2Melphalan 2Cyclophosphamide 2Bortezomib 2Bendamustine Hydrochloride 2selinexor 1loncastuximab tesirine 1ixazomib 1carfilzomib 1Valganciclovir 1Valacyclovir 1Therapeutics 1Tacrolimus 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Lenalidomide 1Ganciclovir 1Foscarnet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Waldenstrom Macroglobulinemia × Valacyclovir × Clear all
NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡